Core Viewpoint - Ying Tai Medical (01501.HK) has entered into a subscription agreement with Kunbo Medical to acquire a total of 91.09 million shares at a price of HKD 3.11 per share, representing a premium of approximately 1.30% over the closing price on the Hong Kong Stock Exchange [1] Group 1 - The total consideration for the subscription is HKD 283 million, excluding transaction costs, and is subject to the terms and conditions of the subscription agreement [1] - Upon completion, the company will hold approximately 17.24% of Kunbo Medical's issued shares, or about 14.38% of the expanded issued shares post-transaction [1] - Kunbo Medical is an innovative enterprise in the field of interventional pulmonology, focusing on the development of minimally invasive diagnostic and therapeutic products for lung diseases, particularly COPD and lung cancer [1] Group 2 - The subscription is expected to further expand the company's strategic layout in the non-vascular interventional field, given Kunbo Medical's rich product line in this area [2] - The board of directors, including independent non-executive directors, believes that the terms of the subscription agreement are fair and reasonable, established on normal commercial terms, and in the overall interest of the company and its shareholders [2]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 近日， 堃博 医疗 发布了2024年度业绩公告。 # 业绩解读 根据堃博医疗2024年度业绩公告，公司在报告期内实现产品销售收入约 5800万人民币 ， 全年净亏损同比缩窄 46%。这一业绩表现主要得益于公司在产品临床进展、市场推广及全球化布局等方面的持续努力。 在临床数据积累方面，公司核心产品取得显著进展： 在市场推广方面，公司产品已在中国多家医院实现临床应用： 在全球化布局方面， 公司海外业务稳步扩展： 截至2024年12月31日，产品已覆盖37个国家和地区，包括美国、英国、德国、法国等发达国家。 TLD靶向去神经消融系统： 慢阻肺急性加重介入治疗产品的上市前临床试验入组顺利，截至2024年12月 31日，已有超过半数受试者完成入组。 LungPro增强现实光学全肺诊疗导航： 4月，中华医学会呼吸病学分会介入学组发布《增强现实光学全 肺诊疗导航引导下肺外周结节诊断、定位及治疗专家共识》，为产品临床应用提供了权威指导。 智衡 ® BroncAblate ...